

February 14, 2023

Ref : KIMIABL/COMP/BSE/22-23/65

To  
**Department of Corporate Affairs- Listing**  
**BSE Limited**  
PhirozJeeJeebhoy Towers,  
Dalal Street, Fort Mumbai-400001

**Scrip Code: 530313 [KIMIABL]**  
**Sub: Outcome of the Board Meeting.**

Dear Sir/Madam,

The meeting of Board of Directors of the Company was held today on Tuesday, February 14, 2023 at 3:00 p.m (IST) at the corporate office of the Company situated at 974, 9<sup>th</sup> floor Aggarwal Millennium Tower-II Netaji Subhash Place Pitampura Delhi-110034.


1. Approval of un-audited financial results of the Company, on standalone basis, as at/for the quarter and nine months ended December 31 2022, in accordance with Regulation 33 of SEBI (Listing Obligation and Disclosure) Requirements) Regulations, 2015.  
The Limited Review Report dated February 14, 2023 issued by the Statutory Auditor of the Company was taken on record. (Copy attached as Annexure A)

We request you to take the above information on record and disseminate the same on your website.

The meeting of Board of Directors concluded at 6:45 pm (IST).

Thanking You,  
Yours faithfully,

For **KIMIA BIOSCIENCES LIMITED**

  
**Lakshay Prakash**  
**Company Secretary & Compliance Officer**  
PLACE: New Delhi  
Encl.: a/a



**KIMIA BIOSCIENCES LIMITED**

Regd. Office/Works  
Village Bhondsi, Damdama Lake Road,  
Gurugram, Haryana-122102  
Tel.: +91 9654746544, 9654206544

Corporate Office  
974, 9<sup>th</sup> Floor, Aggarwal Millennium Tower-II  
Netaji Subhash Place, Pitampura, New Delhi-110034, INDIA  
Tel.: +91 11 47063600, 470630601

**KIMIA BIOSCIENCES LIMITED**

Regd. Office : Village Bhondal, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102

Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com &amp; info@kimiabiosciences.com

Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022**

(₹ Lakhs except EPS)

S. No.	Particulars	Quarter ended			Nine months ended		Year Ended
		31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	2,880.24	4,046.58	3,322.42	10,585.30	9,502.03	12,490.09
II	Other Income	26.40	13.35	21.79	85.00	71.32	93.22
III	<b>Total Income (I+II)</b>	<b>2,906.64</b>	<b>4,059.93</b>	<b>3,344.21</b>	<b>10,670.30</b>	<b>9,573.35</b>	<b>12,583.31</b>
IV	<b>Expenses:</b>						
	a) Cost of materials consumed	2,673.81	3,382.84	2,702.44	8,922.23	7,231.77	9,603.31
	b) Change in inventories of finished goods and work-in-progress	(452.15)	(363.29)	(146.91)	(1,107.74)	(280.20)	(376.96)
	c) Employee benefits expenses	397.71	367.83	405.39	1,151.81	1,139.15	1,508.05
	d) Finance costs	104.91	110.43	90.24	298.41	258.64	364.08
	e) Depreciation and amortisation expense	84.29	82.39	77.26	246.40	218.71	294.10
	f) Other expenses	556.16	591.56	396.36	1,580.16	1,312.10	1,692.55
V	<b>Total Expenses (IV)</b>	<b>3,364.73</b>	<b>4,171.76</b>	<b>3,524.78</b>	<b>11,091.27</b>	<b>9,880.17</b>	<b>13,085.13</b>
VI	<b>Profit/(loss) before exceptional items and Tax (III-V)</b>	<b>(458.09)</b>	<b>(111.83)</b>	<b>(180.57)</b>	<b>(420.97)</b>	<b>(306.82)</b>	<b>(501.82)</b>
VII	Exceptional Items	-	-	-	-	-	-
VI	<b>Profit/(loss) Before Tax (IV-V)</b>	<b>(458.09)</b>	<b>(111.83)</b>	<b>(180.57)</b>	<b>(420.97)</b>	<b>(306.82)</b>	<b>(501.82)</b>
VII	<b>Tax expenses:</b>						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax charge / (reversal)	(112.01)	(28.98)	(46.07)	(102.28)	(77.30)	(131.52)
VIII	<b>Profit/(loss) for the period (VI-VII)</b>	<b>(346.08)</b>	<b>(82.85)</b>	<b>(134.50)</b>	<b>(318.69)</b>	<b>(229.52)</b>	<b>(370.30)</b>
IX	<b>Other Comprehensive Income</b>						
A.	<b>Items that will not be reclassified to Profit or Loss (Net of Tax)</b>						
	- Remeasurement of defined benefit plans	-	-	-	-	-	9.26
B.	<b>Items that will be reclassified to Profit or Loss (Net of Tax)</b>						
X	<b>Total Comprehensive Income for the period (VIII+IX)</b>	<b>(346.08)</b>	<b>(82.85)</b>	<b>(134.50)</b>	<b>(318.69)</b>	<b>(229.52)</b>	<b>(361.04)</b>
XI	Paid up equity share capital (Face value of Rs.1 per equity share)	473.13	473.13	473.13	473.13	473.13	473.13
XII	<b>Other Equity</b>						1,015.70
XIII	<b>Earnings per equity share (not annualised)</b>						
	Basic in Rs.	(0.73)	(0.18)	(0.28)	(0.67)	(0.49)	(0.78)
	Diluted in Rs.	(0.73)	(0.18)	(0.28)	(0.67)	(0.49)	(0.78)

**Other Notes**

- The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable segment as per Ind AS 108 'operating segments'.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14.02.2023

 Date : February 14, 2023  
 Place : New Delhi

FOR KIMIA BIOSCIENCES LIMITED  
  
 Sameer Goel  
 (Managing Director)  
 DIN - 00161786



**Independent Auditor's Review Report on Unaudited Financial Results for the quarter and nine months ended December 31, 2022 Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015, as amended**

To the Board of Directors of Kimia Biosciences Limited

1. We have reviewed the accompanying statement of unaudited financial results ("the Statement") of Kimia Biosciences Limited ("the Company") for the quarter and nine months ended December 31, 2022. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results read with notes therein, prepared in all material respects in accordance with the applicable accounting standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Noida (Delhi – NCR)  
Date: February 14, 2023



For Singhi & Co.  
Chartered Accountants  
Firm Registration No. 302049E

  
Bimal Kumar Sipani  
Partner

Membership No. 088926  
UDIN : 23088926BGXAWX6610